Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Complement changes in falciparum malaria infection.

P Phanuphak, M Hanvanich, R Sakulramrung

    Clinical and Experimental Immunology
    |March 1, 1985
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Pharmacokinetic and Pharmacodynamic Comparison of Once-Daily Efavirenz (400 mg vs. 600 mg) in Treatment-Naïve HIV-Infected Patients: Results of the ENCORE1 Study.

    Clinical pharmacology and therapeutics·2015
    Same author

    Predictors of clinical progression in HIV-1-infected adults initiating combination antiretroviral therapy with advanced disease in the Asia-Pacific region: results from the TREAT Asia HIV observational database.

    Journal of the International Association of Providers of AIDS Care·2013
    Same author

    Assessing adherence in Thai patients taking combination antiretroviral therapy.

    International journal of STD & AIDS·2012
    Same author

    Determinants of epidermal nerve fibre density in antiretroviral-naïve HIV-infected individuals.

    HIV medicine·2012
    Same author

    Cardiovascular risk assessment in persons with HIV infection in the developing world: comparing three risk equations in a cohort of HIV-infected Thais.

    HIV medicine·2011
    Same author

    Prediction of response to antiretroviral therapy by human experts and by the EuResist data-driven expert system (the EVE study).

    HIV medicine·2010

    Plasmodium falciparum malaria infection activates the classical complement pathway, leading to low complement levels (CH50, C3, C1q, C4). These low levels, particularly C3, correlate with severe malaria complications.

    Area of Science:

    • Immunology
    • Infectious Diseases
    • Malariology

    Background:

    • Plasmodium falciparum malaria is a significant global health concern.
    • The complement system plays a crucial role in immune responses to infections.
    • Dysregulation of the complement system may contribute to malaria pathogenesis.

    Purpose of the Study:

    • To investigate complement profiles in Thai adults with acute Plasmodium falciparum malaria.
    • To determine which complement pathways are activated during infection.
    • To assess the relationship between complement levels and malaria complications.

    Main Methods:

    • Sequential measurement of complement components (CH50, C1q, C4, C3, Factor B) in 183 patients.
    • Analysis of complement levels at admission and during treatment.

    Related Experiment Videos

  • Correlation of complement levels with clinical malaria severity and complications.

    • Main Results:

    • Low levels of CH50, C3, C1q, and C4 were observed in a significant proportion of patients upon admission.
    • Factor B levels remained normal, suggesting activation of the classical complement pathway only.
    • Hypocomplementemia, especially low C3, was more pronounced in patients with cerebral, renal, and hepatic complications.
    • Complement components C1q and C4 normalized rapidly after treatment, while C3 and CH50 normalized slower.
    • Persistently low CH50 levels were observed even after C3 normalization.

    Conclusions:

    • Acute Plasmodium falciparum malaria activates the classical complement pathway, leading to significant hypocomplementemia.
    • The degree of hypocomplementemia correlates with malaria severity and specific organ complications.
    • While complement levels generally recover after treatment, CH50 may remain depressed long-term, warranting further investigation.